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Background: Bronchogenic adenocarcinoma is the predominant
histologic subtype of lung cancer, which ranks top in the cancer
mortality in both men and women. Female nonsmokers and adeno-
carcinoma have emerged as a distinct combination in patients with
lung cancer in recent decades. Lung cancer cell lines established
from patients with known clinical characteristics such as gender and
smoking habit would be useful for future research on lung cancer.
Methods: Four new lung adenocarcinoma cell lines (HKULC 1–4)
were established from Chinese patients with primary lung adeno-
carcinomas and with different clinical characteristics with respect to
age, gender, smoking habits, tumor staging, and previous therapy.
They were characterized by immunohistochemical and growth ki-
netic studies, tests for tumorigenicity in nude mice, epidermal
growth factor receptor (EGFR) gene mutation analysis, and in situ
hybridization, and gene expression profiling with Affymetrix Gene-
Chip HG-U133A.
Results: The newly established HKULC lung adenocarcinoma cell
lines were maintained for over 70 passages and demonstrated
morphologic and immunohistochemical features and growth kinetics
of tumor cell lines. One of the four HKULC cell lines, HKULC 3
(derived from a female nonsmoking patient with lung adenocarci-
noma), was found to have a deletion at exon 19 of the EGFR gene.
EGFR in situ hybridization showed no EGFR gene amplification in
these cell lines. HKULC 1 and 4 formed tumor xenografts after
inoculation in nude mice. A list of 71 genes that were differentially
expressed or showing class predictive significance was identified.
These genes included putative tumor suppressor genes (DKK3,
SERPINF1, CDH11, DSC3, and KLF6), genes involved in or related
to the EGFR pathways (ERBB3, MUC1, VAV1), genes involved in
regulation of cell cycle and proliferation (CDKN1A and CDKN2A),
a putative oncogene (EEF1A2), and a gene related to metastasis
(MTSS1).
Discussion: Four new lung adenocarcinoma cell lines were estab-
lished from patients with different clinical characteristics. These
characterized cell lines and their gene expression profiles will
provide resources for studies of lung cancer biology and in vitro
chemotherapeutic drug study.
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Despite continuous efforts and clinical trials to developnew diagnostic, prognostic, and therapeutic methods,
lung cancer remains the leading cause of cancer morbidity
and mortality in Hong Kong1 and worldwide.2 In Hong Kong,
lung cancer accounts for 31% of cancer deaths in men and
25% in women, with a crude incidence rate of 56.8/100,000
population and a crude mortality rate of 48.6/100,000 popu-
lation.1 In recent decades, the combination of female, non-
smoker, and adenocarcinoma has emerged as prominent char-
acteristics in a significant subgroup of lung cancer patients
compared to male, smokers, and squamous cell carcinoma in
the past.3,4 A better understanding of the pathogenesis and
delineation of the major molecular pathways involved in lung
cancer is essential for the identification of new molecular
targets for developing new diagnostic and targeted therapy of
lung cancer.
Despite technical difficulties, lung cancer cell lines
have been established,5–7 including sublines with resistance
or sensitivity to defined chemotherapeutic agents.8–10 In
Hong Kong, we are encountering an increasing proportion of
lung cancer patients who are females and nonsmokers.1 The
aim of this study was to report the establishment and char-
acterization of four new lung adenocarcinoma cell lines
(named HKULC 1–4) from Chinese patients with known
clinical characteristics of age, gender, smoking habits, and
previous therapy. The morphologic, growth kinetics proper-
ties, and epidermal growth factor receptor (EGFR) mutation
status of the cell lines were described. Expression microarray
studies were performed to document the gene expression
profiles of these newly established HKULC cell lines. These
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cancer cell lines (HKULC) could be useful tools for future
lung cancer research and investigation of molecular and thera-
peutic targets for diagnostic and therapeutic intervention.
PATIENTS AND METHODS
Clinical Characteristics
Patient 1 (HKULC 1): Female Nonsmoker, Stage
IIIB, Pericardial Effusion
HKULC1 was derived from the pericardial fluid of a
63-year-old nonsmoking woman with primary adenocarci-
noma of the left lower lobe that invaded the pericardial cavity
(T4N2M0). She presented with pleuropericardial effusion
and a poor performance status. A computed tomography (CT)
scan of the thorax and abdomen showed no other tumor site.
Pericardiocentesis was performed to relieve cardiac tampon-
ade, and no palliative chemoradiation was given (Table 1).
Patient 2 (HKULC 2): Male Smoker, Stage IV,
Pleural Effusion
HKULC 2 was derived from the pleural fluid of a
65-year-old male chronic smoker who presented with right-
side pleural effusion and ascites. Right-side pleurocentesis
for pleural fluid examination confirmed metastatic adenocar-
cinoma. CT scan showed a contrast-enhancing tumor in the
right lower lobe and metastatic nodules in the right middle
and left lower lobes of his lung and in the peritoneal cavity
(T2N3M1). There was no other mass lesion in the liver,
spleen, and kidneys. The patient refused palliative chemo-
therapy, and therapeutic pleurocentesis was performed for
symptomatic relief.
Patient 3 (HKULC 3): Young Female Nonsmoker,
Stage IIIB, Pleural Effusion, Previous Therapy
With Paclitaxel/Carboplatin
HKULC 3 came from the pleural fluid of a 38-year-old
nonsmoking woman who initially presented with chest pain.
CT scan showed a 3-cm peripheral tumor in the right lower
lobe abutting the pleura with satellite nodules within the same
lobe (T4N2M0). CT-guided aspiration of the main tumor
showed adenocarcinoma. She received six cycles of chemo-
therapy with paclitaxel and carboplatin. Initially, stable dis-
ease was achieved for 12 months, but subsequently the tumor
progressed with development of malignant pleural effusion.
Patient 4 (HKULC 4): Male Ex-Smoker, Surgically
Resected Tumor, Stage IIIA
HKULC 4 was cultured from a 52-year-old male ex-
smoker who presented with synchronous tumors of the left
lower lobe (adenocarcinoma, stage T2N2M0 with subcarinal
lymph node metastasis) and the right upper lobe (squamous
cell carcinoma diagnosed by percutaneous transthoracic nee-
dle biopsy) at the time of resection. This cell line was
cultured from the resected left lower lobe adenocarcinoma.
Methods of Collection
All the specimens were collected after informed written
consents were given by the respective patients. Institutional
review board approval had been obtained from the University
of Hong Kong/Hospital Authority Hong Kong West Cluster
Research Ethics Committee for this study. For patients 1
through 3, pleural and pericardial effusions were obtained
with aseptic techniques and centrifuged to collect the malig-
nant cells. For patient 4, fresh tissue from the resected tumor
was cut with fine scissors for cell culture and transplantation
into nude mice. Fresh tissue adjacent to the area used for
culture was snap frozen and kept at 70°C until use. Col-
lected specimens were then seeded into two different types of
culture medium for incubation, ACL4 or RPMI, supple-
mented with 10% fetal bovine serum to maximize the chance
of establishment. ACL4 medium was prepared according to
the protocol published by Oie et al.6 Penicillin and strepto-
mycin (105 U) were added as antibiotic prophylaxis. The cells
were then incubated in 37°C and 5% carbon dioxide. At-
tached cells reaching confluent density were subcultured and
growth maintained in either ACL4 or RPMI, depending on
which medium the cells adapted to in vitro.
Growth Kinetics Study
To determine the growth rate, 105 cells of each cell line
were seeded into 25-cm2 culture flasks with 5 ml of growth
medium. Cell counts were made on days 1, 3, 6, 9, and 12 in
triplicate flasks.
TABLE 1. Summary of the Characteristics of the Four HKULC Cell Lines
Cell Lines HKULC 1 HKULC 2 HKULC 3 HKULC 4
Sex/age Female/63 Male/65 Female/38 Male/52
Smoking habits Lifetime nonsmoker Chronic smoker Lifetime nonsmoker Ex-smoker (had stopped smoking for 1
yr at time of diagnosis
Tissue origin Pericardial fluid Pleural fluid Pleural fluid Resected tumor
Tumor cell type Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma
Staging IIIB IV IIIB IIIA
Previous treatment None None 6 cycles of chemotherapy None
Tumorigenicity in nude mice Yes No No Yes
EGFR mutation in exons
18–21 in respective
cell line
No No Deletion at exon 19 No
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Test for Tumorigenicity in Nude Mice
Tumor cells were harvested and counted with supravital
staining. An inoculum of at least 2 x 105 cells was suspended
in 0.5 ml of the corresponding growth medium. The cell
suspension was then injected subcutaneously beneath the
dorsal skin of a nude mouse, after which the mouse was
maintained and observed for the next 12 months for the
development of xenograft tumor. Where a palpable mass
developed, the mass was harvested at a maximum of 1 cm in
external diameter by humanely killing the respective mouse.
The harvested mass was fixed in 4% formalin, processed into
paraffin sections, examined to confirm the presence of tumor
xenograft, and analyzed for its morphologic characteristics. If
there was no obvious tumor development at the end of 12
months, the mouse was killed and dissected to look for tumor
involvement in internal organs by gross and microscopic
examination. If there was no tumor development with inoc-
ulation content of 2  105 tumor cells, a gradation of inocula
containing 2  106, 2  107, and 2  108 tumor cells were
attempted on three separate mice for each inoculum dose.
Morphologic Characteristics and
Immunohistochemical (IHC) Studies
Harvested tumor cells of each cell line were centri-
fuged, fixed, and paraffin-embedded into a cell block accord-
ing to routine cytology procedures. A piece of tumor (DL31)
adjacent to that used for cell culture establishment was also
sampled from patient 4 for comparison with an HKULC 4
xenograft. The cultured cells, xenografts, and the resected
tumor were characterized for their morphologic characteris-
tics by routine hematoxylin and eosin stain, mucin content,
and their phenotypic patterns by IHC using a panel of
monoclonal antibodies against cytokeratins (CK7 [DAKO,
M7018], CK20 [DAKO, M7019]), the thyroid transcription
factor TTF-1 (DAKO, M3575), and the proliferation marker
MIB-1 (DAKO, M7240).
Gene Expression Profiling Analysis with
Affymetrix Genechip U133A
For the cultured cancer cells, at least 2 107 cells were
harvested and total RNA was extracted with the RNeasy
Miniprep (Qiagen) protocol. For the tumor block of DL31,
normal tissue was trimmed away, resulting in 90% tumor
by area. Fifty frozen sections (10 m/section) were used for
total RNA extraction using the RNeasy Miniprep (Qiagen)
protocol. The quality of the total RNA was checked with
denaturing formamide gel electrophoresis, which showed two
sharp and distinct bands of 18S and 28S. Quality check was
also done by the Agilent Bioanalyzer with graphic analysis
showing two distinct peaks of 18S and 28S without additional
peaks of degradation. The total RNA was then hybridized
onto Affymetrix GeneChip HG-U133A according to standard
protocols.11
Absolute signals from individual chips were captured
and processed with the standard MicroArray Suite 5.0 soft-
ware (Affymetrix). Captured signals were further scaled and
normalized by an in-house Visual Basic software MATRIX
(MicroArray Transformation in Excel) Version 1.30 written
by Luc Girard at the University of Texas Southwestern
Medical Center at Dallas. The MATRIX program allowed
input of multiple CHP files (saved in text file format) from
MicroArray Suite 5.0 into an Excel spreadsheet where nor-
malization, comparison of arrays using log ratios and t tests,
color display, and hierarchical clustering were performed.
Captured gene expression signals were normalized to median
expression level across all chips in this experiment. Genes
with signals designated as absent in more than 50% of the
samples were filtered out. The normalized gene expression
signals were then log-transformed to the base 2, and log ratios
comparing different sample groups could be performed ac-
cording to the following formula: log ratio  log2 (mean
HKULC/mean NHBEC), where mean HKULC was the
mean of signals of all four (HKULC 1– 4) cell lines, and
mean NHBEC was the mean of signals of four normal
human bronchial epithelial cell lines (including NHBE
[Clonetics], SAEC [Clonetics], BEAS-2B cell lines [ATCC
CRL-9609], and HBEC1-KT12). A log ratio of 2.00 indi-
cated increased expression of at least fourfold of mean
HKULC compared to mean NHBEC. A log ratio of 2.00
indicated reduced expression of at least fourfold in mean
HKULC compared to mean NHBEC.
To compare the gene expression levels between
HKULC 4 and DL31, log ratios of gene expression signals of
HKULC 4 compared to those of DL31 were obtained. The
Pearson correlation coefficient of the gene expression levels
of HKULC and DL31 was also calculated. Unsupervised
hierarchical clustering was performed on the four HKULC
cell lines, DL31, and the four NHBEC lines to look for
similarity of gene expression profiles of the samples.
Class prediction with support vector machine with
leave-one-out analysis was performed using the BRB Array-
Tools version 3.4.0 developed by Richard Simon and Amy
Peng Lam from the National Cancer Institute (NCI),13 to
identify a gene list that distinguishes cancer from normal
bronchial epithelial cells. To validate the prediction accuracy
of the identified gene list, Affymetrix GeneChip U133A data
of a panel of 13 NCI adenocarcinoma cell lines (NCI H1437,
H1648, H1650, H1819, H1975, H1993, H2009, H2087,
H2126, H2347, HCC461, HCC515, HCC1833; data available
from J.D.M.) were used as a separate test set in the analysis.
We first assigned available GeneChip data into two sets with
set A including GeneChip data from the four HKULC cell
lines and the four normal human bronchial epithelial cell lines
(eight samples), and set B with NCI adenocarcinoma cell
lines and the same four normal human bronchial epithelial
cell lines (17 samples). We first used set A as a training set to
identify a group of classifier genes that distinguished between
HKULC cell lines and normal bronchial epithelial cell lines.
This group of genes was then used for validation with set B
as the test set. The whole process was repeated, reversing set
B as the initial training set and set A as the test set, until a list
of classifier genes that yielded 100% sensitivity and specific-
ity in either comparison were obtained.
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EGFR Mutation at Exons 18–21
Total genomic DNA was extracted from the respective
cell lines according to standard protocol. Exons 18–21 of the
EGFR gene were analyzed for mutations according to our
previous protocol.14
In Situ Hybridization (ISH) for Detection of EGFR
Overexpression
EGFR gene copy number was analyzed by chromo-
genic ISH, with digoxigenin-labeled EGFR and chromosome
7 DNA probes (SPoT-Light probes, Zymed) targeting the
whole EGFR gene and chromosome 7 centromere, respec-
tively, on tumor cell blocks. At least 100 nonoverlapping
tumor cells were scored. The number of signals for chromo-
some 7 control and EGFR probes, respectively, were scored
for each counted tumor cell.
RESULTS
Cell Culture Characteristics
All cell lines were maintained in continuous culture for
at least 70 passages. The four cell lines had different mor-
phologic features. HKULC 1 formed tightly packed attached
cells of medium size that tended to pile up before reaching
confluency (Fig. 1a), HKULC 2 (Fig. 1b) and HKULC 4 (Fig.
1d) formed confluent and mainly monolayer sheets of at-
tached cells of medium size. HKULC 3 formed colonies and
clusters of attached cells, with marked variation of cell size
and frequent multiple or multilobated nuclei (Fig. 1c).
Growth Kinetic Study
HKULC 2 and 4 showed a short lag phase of 1 to 2
days. HKULC 2 showed the fastest growth rate, whereas
HKULC 4 grew more steadily (Fig. 2). Both HKULC 1 and
3 showed an initial lag phase of 4 to 5 days followed by an
accelerated phase (Fig. 2). This feature might be related to the
formation of cell clusters in these cell lines before spreading
to form confluent tumor cell layers. HKULC 1, 2, and 3
showed similar doubling times, at the linear growth phase, of
about 25 hours, whereas HKULC 4 showed a doubling time
of 33.5 hours.
Test for Tumorigenicity in Nude Mice
HKULC 1 and 4 formed tumor xenografts of 1 cm in
about 6 to 8 weeks (Table 1). The parental tissue for HKULC
4 was also transplantable and developed into xenograft. The
xenograft obtained from these cell inoculations and the
HKULC 4 parental tissue could further develop into tumors
after retransplantation into separate nude mice. The time for
xenograft establishment was 3 to 4 weeks after inoculation
(when a subcutaneous bulge was visible) and by 6 to 8 weeks
after inoculation, the xenograft would attain the external
dimension of 1 cm for xenograft harvesting.
HKULC 2 and 3 failed to produce xenograft 12 months
after tumor cell inoculation with at least three separate at-
tempts for each dose of tumor cell inoculation.
FIGURE 2. Growth curves of the four newly established
HKULC lung adenocarcinoma cell lines at their 70th passage.
FIGURE 1. Photomicrographs of
the four newly established HKULC
lung adenocarcinoma cell lines at
the 70th passage. a: HKULC 1 show-
ing piling up of tumor cells growing
in the center. b: HKULC 2 showing
monolayers of tumor cell growth. c:
HKULC3 showing tumor cells cluster-
ing together without forming a con-
fluent layer of tumor cells. d: HKULC
4 showing a confluent layer of tumor
cell growth with some layering of
cells at the center.
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Morphologic and Differentiation
Characteristics of Tumor Cells and Xenografts
HKULC 1 showed fairly uniform population of medi-
um-sized cells containing single nuclei. Its xenograft showed
high-grade tumor cells arranged in solid clusters with cribri-
form formations (Fig. 3a). Intracytoplasmic mucin globules
were present in occasional cells. HKULC 4 showed mild
variation in cell size with occasional multinucleate forms.
The xenograft consisted of high-grade tumor cells arranged in
compact solid clusters with scattered areas showing acinar
differentiation (Fig. 3b). Compared to the xenograft, the
resected parent tumor showed more frequent acinar differen-
tiation, but solid areas displaying large clusters of tumor cells
were also present (Fig. 3c). Mild inflammatory cell infiltra-
tion was present, most prominent around areas of necrosis.
No intracytoplasmic mucin formation was observed in the
parent or transplanted tumor. HKULC 2 consisted of pleo-
morphic tumor cells with eccentric nuclei and no mucin
formation. The cancer cells of HKULC 3 showed marked
variation in cell size with frequent large bizarre multinucleate
forms and occasional fine granules of intracytoplasmic mu-
cin. For tumor cell markers, all the cell lines and xenografts
were CK7 positive (Fig. 3d) and CK20 negative. HKULC 2,
3, and 4 showed TTF1 expression in at least 10% of tumor
cells (Fig. 3e), whereas HKULC 1 was negative. All the cell
lines showed 30% to 50% proliferating cells as indicated by
the MIB1 proliferation marker (Fig. 3f).
Mutation Status and In Situ Hybridization
Analysis (ISH) of EGFR
HKULC 3 showed deletion of amino acids 756–760 of
exon 19 (Table 1). No mutation was found in HKULC 1, 2,
and 4 at exons 18–21. ISH showed that HKULC 1 and 4 were
near disomy, whereas HKULC 2 and 3 were near tetrasomy
for chromosome 7 (Fig. 4; Table 2). A slight increase in
EGFR to chromosome 7 copy number resulting in a mean
ratio of 1.11–1.31 was observed in the cell lines (Table 2).
Expression Profiling with Affymetrix Genechip
When compared to normal bronchial epithelial cells,
genes that showed either (1) a higher or lower expression by
fourfold (log ratio 2.00 or 2.00) and statistically sig-
nificant difference of mean expression level across all four
HKULC cell lines at p 0.05 by t tests or (2) class-predictive
significance (adenocarcinoma cell lines, either the HKULC
group or the NCI adenocarcinoma group versus normal bron-
chial epithelial cell lines) by support vector machine with
leave-one-out analysis, were identified (detailed in supple-
mentary document sheet 1 available online). By criterion 1,
there were 84 genes that showed fourfold altered expression
levels (supplementary document sheet 2). Among them, 61
FIGURE 3. Photomicrographs of xenografts and cell blocks derived from the four HKULC cell lines. a: HKULC 1 xenograft
(hematoxylin and eosin staining) showing solid tumor clusters and gland forms. b: HKULC 4 xenograft (hematoxylin and eosin
staining) showing solid tumor clusters separated by narrow connective tissue septa. c: Parent tissue of HKULC 4 (hematoxylin
and eosin staining) showing solid tumor clusters and high tumor-to-stroma ratio. d: HKULC 3 cell block, positive immunohis-
tochemical staining for CK7. e: HKULC 4 xenograft positive TTF1 staining in about 50% of tumor cells. f: HKULC 2 cell block,
positive MIB1 staining in 50% of tumor cells.
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demonstrated statistical significance of p  0.05 by t tests
(1610 genes showed statistical significance at this level by t
tests). By criterion 2, 17 classifier genes were found that were
able to predict the class phenotype of both HKULC cell lines
and NCI adenocarcinoma cell lines, respectively, from nor-
mal bronchial epithelial cell lines with 100% sensitivity and
specificity. Seven genes listed by criteria 1 and 2 overlapped
with each other and a final list of 71 genes (Table 3) that fit
either criteria 1 or 2 or both was obtained.
When the gene expression data of HKULC4 and its
parental tissue (DL31) were compared, the Pearson coefficient
of correlation of the gene expression data from the two samples
was r  0.92. Unsupervised hierarchical clustering analysis of
the four cancer cell lines, four normal bronchial epithelial cells,
and DL31 showed that HKULC 4 and DL31 clustered together,
supporting a high correlation of their expression profiles (Fig. 5).
FIGURE 4. In situ hybridization for evaluation of chromo-
some 7 and endothelial growth factor receptor (EGFR) gene
copy number in HKULC 2 cell line. a: Chromosome 7 probe
showing three to four signal copies per cell. b: EGFR probe
showing four to five signal copies per cell.
TABLE 2. The Average Copy Number of Endothelial
Growth Factor Receptor (EGFR) Gene Compared to
Chromosome 7 for the Four HKULC Cell Lines
chr 7 Signal/Cell EGFR Signal/Cell EGFR Signal/Cell
HKUL C1 1.95 2.55 1.31
HKUL C2 3.93 4.63 1.18
HKUL C3 4.31 4.79 1.11
HKUL C4 2.19 2.73 1.25
FIGURE 5. Unsupervised hierarchical clustering of the
HKULC cell lines, DL31, and the normal bronchial human
epithelial cell lines. Note that HKULC 4 and DL31 cluster to-
gether. NHBE (Clonetics), normal human bronchial epithelial
cells; SAEC (Clonetics), smallairway epithelial cells; BEAS-2B
(ATCC CRL-9609), a SV40 T antigen-immortalized bronchial
epithelial cell line; HBEC 1-KT, a Cdk4/hTERT-immortalized
bronchial epithelial cell line.12
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A list of 202 genes differing by fourfold or more in either
direction was found (supplementary document sheet 3). More
than 50% of these genes were adhesion molecules, immuno-
globulin or immunoglobulin receptor genes, cell surface binding
proteins, chemokine receptor genes, collagen, and major histo-
compatibility molecules.
DISCUSSION
The four lung adenocarcinoma cell lines (HKULC 1–4)
were all newly established from patients with primary lung
adenocarcinomas. They displayed a variable degree of nu-
clear pleomorphism, with HKULC 3 showing admixtures of
large tumor cells with multinucleation (Fig. 1c). HKULC 2
and 4 had a shorter initial lag phase and formed confluent
tumor cell layers, whereas HKULC 1 and 3 displayed tumor
cell aggregation (Fig. 1a and c). The tendency for tumor cells
to form clusters was apparently not associated with transplant-
ability, as only HKULC 1 but not HKULC 3 formed tumor
xenografts in nude mice (Table 1). Although only four cancer
cell lines were available for analysis, comparison of expression
profiles between cell lines with differences in transplantabil-
ity and tendency of aggregation did not yield genes that
showed significant differential expression (data not shown).
EGFR mutations have been found to be more common
in lung adenocarcinomas in nonsmoking women, especially
well-differentiated tumors with bronchioloalveolar differen-
tiation. Among the four cancer cell lines, EGFR exon 19
deletion was found only in HKULC 3 (Table 1), which was
derived from a female nonsmoker whose tumor cells ex-
pressed the TTF1 pneumocyte differentiation marker. The
other tumor cells, including HKULC 1 from a female non-
smoker but which did not show TTF1 expression, and
HKULC 2 and 4, which were from current or previous
smokers, did not show EGFR mutations. ISH showed near
tetrasomy for chromosome 7 in HKULC 2 and 3 and near
disomy for HKULC 1 and 4. Amplification of EGFR was not
observed, with all cell lines showing not more than 1.31 copies
of EGFR to every chromosome 7 control probe (Table 2).
Unsupervised hierarchical clustering of the HKULC
and normal bronchial epithelial cell lines showed that the
expression profile of HKULC 3 clusters separately from
the other cell lines. Several factors could have accounted for
the separation of HKULC 3 from the other cell lines, such as
EGFR exon 19 deletion, previous chemotherapy, and the
presence of numerous large, pleomorphic, and multinucleated
tumor cells. To evaluate the effects of EGFR mutation on the
clustering pattern, the microarray data set included EGFR
mutant-bearing cell lines, such as H1650 and H1975, for
hierarchical clustering analysis. The results showed that
HKULC 3 and these EGFR mutant cell lines did not cluster
together, indicating that EGFR mutation alone was not the
major factor determining the clustering pattern (result not
shown).
In this study, the gene expression profiles were docu-
mented as part of the characterization of these cell lines so
that the information would be available as reference for future
research studies using these cell lines. As a preliminary
analysis, the expression profiles of these HKULC cell lines
were compared to the four normal human bronchial epithelial
cell lines and 13 NCI adenocarcinoma cell lines to look for
any candidates of differentially expressed genes.
Among the 71 genes listed (Table 3), some were
putative tumor suppressor genes showing four- to eightfold
lower expression levels, namely, DKK3 (log ratio of individ-
ual HKULC cell lines: 2.43 to 4.25), SERPINF1 (log
ratio: 3.78), CDH11 (log ratio: 3.76), DSC3 (log ratio:
2.73 to 3.33), and Kruppel-like factor 6 (KLF6) (log
ratio: 2.28 to 2.75), in HKULC cell lines compared to
normal human bronchial epithelial cell lines. DKK3 has been
reported to demonstrate tumor-suppressing activities in a
variety of tumors including tumors of the lung, kidney,
urinary bladder, pancreas, and prostate and in different tumor
cell lines.15 DKK3 has been found to be down-regulated in
lung cancer cell lines by promoter hypermethylation, and
treatment of these cell lines with 5-aza-cytidine restored its
tumor-suppressing ability.16 SERPINF1, also known as pig-
ment epithelium-derived factor, was also thought to possess
tumor-suppressing properties via its antiangiogenic effects.
HeLa cells bearing the wild-type allele show tumor-suppress-
ing abilities, whereas HeLa cells bearing the mutant allele
demonstrate loss of growth inhibition.17 Transfection of
SERPINF1 into colonic adenocarcinoma cell lines restored
tumor-suppressing properties with reduced tumor growth and
tumor microvessel densities18 in the pulmonary metastatic
tumor model. The expression of SERPINF1 at mRNA and
protein levels had also been found to be reduced in lung tumors,
and this reduction in the level of expression was correlated
with tumor microvessel density and poor survival.19
Two members of the cadherin superfamily were found
in this list of 71 genes. CDH11 has been proposed as a tumor
suppressor gene in retinoblastoma.20 Its expression in pulmo-
nary metastasis model of osteosarcoma cell lines restored
tumor-suppressing function.21 Desmocollin (DSC3) is also a
member of the cadherin molecules. DSC3 had been reported
to show loss of expression in breast tumor cells via promoter
hypermethylation.22 KLF6 had been shown to exert its tumor-
suppressing activities via inhibition of c-Jun proto-oncogene–
mediated cellular proliferation.23 The expression of KLF6 had
been found to be reduced in prostate24 and colorectal cancer
cells.25 All these genes, namely, DKK3, SERPINF1, CDH11,
DSC3, and KLF6, are potential tumor suppressor genes that
were found to be down-regulated in the newly established
HKULC cell lines 1–4 compared to normal human bronchial
epithelial cells. The new cancer cell lines could act as suitable
handles for further studying the role of these putative tumor
suppressor genes in lung cancer.
Some of the genes could be related to elements in the
EGFR signaling pathway, including ERBB3, MUC1, and VAV1.
The EGFR gene and chemotherapeutic agents targeting ele-
ments in its downstream signaling pathway are under intensive
investigations as possible therapeutic interventions for manage-
ment of lung cancer.26 The EGFR gene family includes EGFR
(ERBB1 or HER1), HER2 (EGFR2 or ERBB2/NEU), HER3
(EGFR3 or ERBB3), and HER4 (EGFR4 or ERBB4).27 Each of
them displays distinct characteristics with ERBB2 showing in-
tense kinase activity, but ERBB3 showing no kinase activity at
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all.27 Studies have shown that the female gender, nonsmoker
status, Asian ethnic origin, and carrying activating EGFR mu-
tation are predictors of good clinical response to EGFR tyrosine
kinase inhibitors.28,29 Like EGFR mutation, ERBB2 mutations
are found to be associated with Asian origin, female gender, and
nonsmoker status,30 and increased copy number of HER2 has
been reported to be associated with response to EGFR tyrosine
kinase inhibitor.31 ERBB2 overexpression has been found to
increase the sensitivity of lung cancer cells to gefitinib via
heterodimerization to form the ERBB2/ERBB3 complex.32 Rel-
atively fewer studies focus on ERBB3 itself in lung cancer. One
recent study reports on ERBB3 overexpression and association
with response to gefitinib in lung cancer patients.33 ERBB3 could
thus be one potential target for therapeutic intervention in lung
cancer. Among the ERBB gene family, ERBB3 showed higher
level of expression of at least threefold (log ratio of individual
HKULC cell line: 1.84–3.36) in all the four HKULC cell lines
when compared to normal human bronchial epithelial cell lines
(Table 3). The HKULC cell lines could be suitable materials for
in vitro drug sensitivity tests, for example, in testing the effects
of anti-HER3 antibody on the growth of lung cancer cells.
Expression levels of ERBB1, ERBB2, and ERBB4 in all the four
HKULC cell lines were not more than twofold altered (higher or
lower) compared to the NHBEC cell lines, except that HKULC
3 showed about a threefold higher level of ERBB2 expression
(log ratio of HKULC 3: 1.27, HKULC 1: 0.41, HKULC 2:
0.57, HKULC 4: 0.71) than NHBEC cell lines. HKULC 3 was
also the cell line bearing EGFR gene deletion at exon 19 (Table
1). The observation that the HKULC 3 cell line showed high
expression levels of both ERBB2 and ERBB3 could imply, as
suggested in a previous study of breast cancer, that ERBB2/
ERBB3 could form oncogenic functional heterodimers to pro-
mote tumor proliferation.34
MUC1 overexpression has also been reported to be
associated with ERBB1, ERBB2, ERBB3, and ERBB4 expres-
sion.35 It has been shown that MUC1 interacts with various
ERBB proteins to potentiate signal transduction along the
EGFR pathway by activation of mitogenic mitogen-activated
protein kinases.35 MUC1 is also highly expressed in the four
HKULC cell lines (log ratio of HKULC versus mean NH-
BEC: 3.54–5.36, i.e., eight- to 30-fold overexpression).
Overexpression of MUC1 has been reported in various tumor
and cancer cell lines including various subtypes of lung
adenocarcinomas36 and breast and colorectal cancer, and its
expression has been correlated with malignant transformation
and tumor invasiveness.37,38 MUC1 encodes for a tumor-
associated antigen that is currently under evaluation as a
target for tumor vaccine development in non-small cell lung
cancer.39,40 The four HKULC cell lines with MUC1 overex-
pression could be useful for in vitro testing of MUC1 as a
potential therapeutic target.
The VAV1 gene was found to be highly expressed in the
HKULC 3 and 4 cell lines. VAV1 is a proto-oncogene mainly
expressed in hemopoietic cells and the VAV1 protein belongs
to a family of VAV proteins that could bind to various cell
surface receptors including EGFR, resulting in EGFR activa-
tion and promotion of cellular growth and proliferation
through downstream signaling.41 VAV1 has also been found
to show synergistic action with EGFR and demonstrated
proto-oncogenic properties by promoting pancreatic cancer
cell proliferation.42
ERBB3, MUC1, and VAV1 were the discriminatory
genes common to all four HKULC cell lines. Thus, apart
from mutation of EGFR, these could interact with and assist
in the activation of the EGFR pathway.
From the list of genes in Table 3, other genes that could
represent potential targets for manipulation in these HKULC
cell lines include genes that are involved in control of cell
cycle and proliferation, including CDKN1A (log ratio: 2.28
to3.94, indicating four- to eightfold lower levels of expres-
sion in HKULC cell lines compared to normal human bron-
chial epithelial cell lines) and CDKN2A (log ratio: 3.56,
i.e., more than eightfold lower levels of expression in
HKULC cell lines compared to mean NHBEC). CDKN1A has
been found to interact with MUC1.43 Suppressed expression
of CDKN2A by promoter hypermethylation has been well
reported in lung cancer.44,45 The low expression of CDKN1A
and CDKN2A may reflect their roles in the control of cell
cycles and proliferation in these HKULC cell lines. Other
targets with potential roles in lung cancer development requiring
further investigation include EEF1A2 and MTSS1. EEF1A2 is a
putative oncogene in ovarian cancer46 and is also highly ex-
pressed in all the HKULC cell lines. The expression of the
MTSS1 gene has been reported to inhibit metastasis in bladder
cancer47 and MTSS1 gene showed low expression in the
HKULC cell lines.
One of the theoretical concerns regarding the use of
cultured cells as research material is that they could acquire
genetic changes during in vitro propagation so that they no
longer represent the original tissues from which they were
derived. In this study, we have demonstrated a close histo-
logic resemblance of HKULC 4 xenograft tumor and its
parent tumor tissue (Fig. 3). We have also shown a high
correlation coefficient (0.92) between the expression profile
of HKULC 4 and its parent tumor DL31. Most of the genes
that showed at least fourfold difference were immunoglobulin
genes, adhesion molecules, or genes found in the cellular
matrix. The differential expression of genes between a cell
line and its parent tissue could reflect the repertoire of genes
involved in cell-matrix interaction in the in vivo environment.
The 92% correlation of gene expression levels between the
HKULC 4 cell line and its parent tissue and their clustering
together indicates a close resemblance in the biological ac-
tivities engaged in the maintenance of in vitro propagation
and validates the use of cancer cell cultures as surrogate
models of cancer growth. Similar observations have been
made in other cancer types. When breast cancer cell lines
were compared to their parental tissues, a satisfactory repre-
sentation of the parental tumor characteristics in terms of
gene mutations and expression was reported.48
In summary, we have established four new primary
lung adenocarcinoma cell lines from Chinese patients, includ-
ing female nonsmokers, with different clinical characteristics,
culture, and expression profiles. These cell lines could serve
as useful tools for further functional studies and drug sensi-
tivity testing in translational research in lung cancer.
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TABLE 3. List of 71 Genes Identified in Comparison between the HKULC Cell Lines and Normal Bronchial Epithelial Cell Lines
(Continued)
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TABLE 3. (Continued )
HKULC1, HKULC2, HKULC3, HKULC4 vs Mean NHBEC signals: values represent the log ratios of gene expression signals from individual HKULC cell lines compared with
mean NHBEC signals. Positive values (higher expression in HKULC cell lines compared with NHBEC cell lines) 2.00 are highlighted in red. Negative values (lower expression
in HKULC cell lines compared with NHBEC cell lines) 2.00 are highlighted in green.
T-test Mean HKULC signals vs Mean NHBEC Signals: listing of the p value of student t tests of the respective genes when comparing all 4 HKULC cell lines with the 4 NHBEC
cell lines, with two-tails and unequal variance assumed.
Class Predictors: those genes found to be class predictors with respect to either HKULC cell lines against NHBEC cell lines or NCI adenocarcinoma cell lines against NHBEC
cells are labeled with ‘P’.
Color Display: the gene expression levels are represented with a white to blue scale so that the lighter colors represent low expression and deeper colors represent high expression.
NHBEC: Normal Human Bronchial Epithelial cell line.
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